

## **Ipsen announces its corporate agenda for 2014**

**Paris (France), 23 December 2013** – Ipsen (Euronext: IPN; ADR: IPSEY) today announced its corporate agenda\* for 2014:

28 January 2014:	Full year 2013 sales
28 February 2014:	Full year 2013 results
30 April 2014:	First quarter 2014 sales
4 June 2014:	General shareholders' meeting
12 June 2014:	Payment of 2013** dividend
29 August 2014:	First half 2014 sales & results
29 October 2014:	First nine months 2014 sales

\* This financial calendar is for indicative purposes only and the Group could change its publication dates should it deem it necessary

\*\* Pending approval of the Board of directors (27<sup>th</sup> February 2014) and of the General shareholders' meeting (4<sup>th</sup> June 2014)

### **About Ipsen**

Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2012. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and uro-oncology. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2012, R&D expenditure totalled close to €250 million, representing more than 20% of Group sales. The Group has close to 4,900 employees worldwide. Ipsen's shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the "Service de Règlement Différé" ("SRD"). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit [www.ipsen.com](http://www.ipsen.com).

### **For further information:**

#### **Media**

##### **Didier Véron**

Senior Vice-Président, Public Affairs  
and Communication  
Tel.: +33 (0)1 58 33 51 16  
Fax: +33 (0)1 58 33 50 58  
E-mail: [didier.veron@ipsen.com](mailto:didier.veron@ipsen.com)

##### **Brigitte Le Guennec**

Media and Public Relations Officer  
Tel.: +33 (0)1 58 33 51 17  
Fax: +33 (0)1 58 33 50 58  
E-mail : [brigitte.le.guennec@ipsen.com](mailto:brigitte.le.guennec@ipsen.com)



**Financial Community**

**Pierre Kemula**

Vice President, Corporate Finance, Treasury and  
Financial Markets

Tel.: +33 (0)1 58 33 60 08

Fax: +33 (0)1 58 33 50 63

E-mail: [pierre.kemula@ipsen.com](mailto:pierre.kemula@ipsen.com)

**Stéphane Durant des Aulnois**

Investor Relations Officer

Tel.: +33 (0)1 58 33 60 09

Fax: +33 (0)1 58 33 50 63

E-mail: [stephane.durant.des.aulnois@ipsen.com](mailto:stephane.durant.des.aulnois@ipsen.com)

**Thomas Peny-Coblentz**

Investor Relations Manager

Tel.: +33 (0)1 58 33 56 36

Fax: +33 (0)1 58 33 50 63

E-mail: [thomas.peny-coblentz@ipsen.com](mailto:thomas.peny-coblentz@ipsen.com)